Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Colorectal Cancer Clear all
Terminated Phase 1 Interventional Results available

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591
View directory record Official record
Conditions
Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions
PF-06952229, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 27, 2026, 1:45 PM EDT
Completed Phase 1 Interventional Results available

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

NCT01451632
View directory record Official record
Conditions
Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence
Interventions
MM-121, Irinotecan, Cetuximab
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Oct 27, 2026, 1:45 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluating Novel Therapies in ctDNA Positive GI Cancers

NCT05482516
View directory record Official record
Conditions
Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
Interventions
Atezolizumab, Bevacizumab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 27, 2026, 1:45 PM EDT
Active, not recruiting Phase 1 Interventional

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

NCT05838768
View directory record Official record
Conditions
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Interventions
HRO761, pembrolizumab, irinotecan
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 1:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer

NCT02865135
View directory record Official record
Conditions
Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus
Interventions
DPX-E7 vaccine, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 27, 2026, 1:45 PM EDT
Completed Not applicable Interventional

Collection of Patient-Reported Symptoms and Performance Status Via the Internet

NCT00417040
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Leukemia, Multiple Myeloma
Interventions
internet-based intervention, assessment of therapy complications, Questionnaire Administration
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
95
States / cities
Castro Valley, California • Fremont, California • Martinez, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 27, 2026, 1:45 PM EDT
Completed Not applicable Interventional Results available

Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC

NCT03567850
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Problem solving Skills Training
Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 27, 2026, 1:45 PM EDT
Terminated Not applicable Interventional

A Clinical Study To Measure The Effect Of Use Of Artificial Intelligence (AI) Enabled Computer Aided Detection (CADe) Assistance Software In Detecting Colon Polyps During Standard Colonoscopy Procedures

NCT04555135
View directory record Official record
Conditions
Colon Polyp, Colon Neoplasm, Colon Adenoma
Interventions
EndoVigilant Software
Device
Lead sponsor
EndoVigilant Inc
Industry
Eligibility
45 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Mission Viejo, California • Waterbury, Connecticut • Greenbelt, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 27, 2026, 1:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

PRE-ISPY Phase I/II Oncology Platform Program

NCT05868226
View directory record Official record
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 1:45 PM EDT
Recruiting Phase 2 Interventional

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

NCT06824064
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions
RBS2418, Placebo
Drug
Lead sponsor
Riboscience, LLC.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Newark, Delaware • Kingwood, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 27, 2026, 1:45 PM EDT
Active, not recruiting Phase 2 Interventional

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

NCT05961709
View directory record Official record
Conditions
Colon Cancer
Interventions
Cemiplimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Gilbert, Arizona • Jacksonville, Florida • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 1:45 PM EDT
Recruiting Phase 2 Interventional

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

NCT07407647
View directory record Official record
Conditions
Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Biospecimen Collection, Prasterone, Survey Administration
Procedure · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 27, 2026, 1:45 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

NCT05099549
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor
Interventions
AFM24, SNK01
Drug · Biological
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 27, 2026, 1:45 PM EDT
Withdrawn Phase 2 Interventional

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

NCT06410534
View directory record Official record
Conditions
Colorectal Cancer, Gastroesophageal Cancer
Interventions
nivolumab, ipilimumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 27, 2026, 1:45 PM EDT
Terminated Phase 2 Interventional Results available

Sunitinib and Capecitabine for First Line Colon Cancer

NCT00961571
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
sunitinib and capecitabine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 27, 2026, 1:45 PM EDT
Completed No phase listed Observational

Partial Wave Spectroscopic Detection of Colon Cancer Risk

NCT01095432
View directory record Official record
Conditions
Ulcerative Colitis, Colon Cancer
Interventions
PWS Testing
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 27, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

NCT00865709
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Wichita, Kansas • Metairie, Louisiana • Brockton, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 27, 2026, 1:45 PM EDT
Terminated Phase 2 Interventional Results available

Neo-Adjuvant FOLFOX for Rectal Carcinoma

NCT00832299
View directory record Official record
Conditions
Rectal Neoplasms
Interventions
FOLFOX, total mesorectal excision (TME)
Drug · Procedure
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 27, 2026, 1:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Colorectal Cancer Screening With Improved Shared Decision Making

NCT01519999
View directory record Official record
Conditions
Colorectal Cancer Screening, Shared Decision Making
Interventions
Shared Decision Making for Colorectal Cancer Screening
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
50 Years to 75 Years
Enrollment
206,721 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 27, 2026, 1:45 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

NCT00022698
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine, Irinotecan
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
17
States / cities
Birmingham, Alabama • Loma Linda, California • Norwich, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 27, 2026, 1:45 PM EDT
Terminated No phase listed Observational

Non-Invasive Prediction of Colorectal Neoplasia

NCT01815463
View directory record Official record
Conditions
Colonic Polyps, Polyposis Coli, Colorectal Cancer
Interventions
Not listed
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
2,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 27, 2026, 1:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Screen to Save 2: Rural Cancer Screening Educational Intervention

NCT04414306
View directory record Official record
Conditions
Cancer, Colorectal Cancer
Interventions
Online educational video and website module
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 27, 2026, 1:45 PM EDT
Completed Not applicable Interventional

Survivor Choices for Eating and Drinking - Colorectal Cancer

NCT02965521
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, ColoRectal Cancer
Interventions
Website and text messages
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 27, 2026, 1:45 PM EDT
Recruiting Not applicable Interventional

The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial

NCT06565052
View directory record Official record
Conditions
Rectal Cancer, Colorectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
Interventions
Prehabilitation Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 1:45 PM EDT